Abstract: Compounds are disclosed according to the formula ##STR1## or an optical isomer thereof. The compounds of Formula I are cyclic AMP phosphodiesterase inhibitors useful as antithrombotic and inotropic agents and the like in mammals.
Abstract: A method for assaying for a ligand analyte which is a member of a specific binding pair ("sbp member") consisting of ligand and its complementary receptor is disclosed. The ligand analyte has a binding site in common with an interfering substance present in a sample suspected of containing the analyte. The interfering substance has at least two binding sites. The method comprises combining in an assay medium without intervening separation (1) the sample, (2) a blocking receptor which does not bind to the ligand and does bind to the interfering substance, thereby blocking the binding of a common receptor to the interfering substance, and (3) a common receptor which binds to the common binding site. Any additional members of a signal producing system capable of producing a detectable signal in relation to the amount of analyte in the sample are added to the assay medium. Next, the assay medium is examined for the presence of a detectable signal.
Abstract: Compounds useful in treating cardiovascular disorders such as thrombosis, hypertension and atherosclerosis are depicted in formulas (1), (2) and (3): ##STR1## wherein: A is --C.tbd.C--, trans --HC.dbd.CH--, --CH.sub.2 CH.sub.2 -- or --CH.dbd.CHCH.sub.2 --;X is lower alkoxy, hydroxy, or (2,2,2)-trifluoroethoxy;Y is hydrogen, exo-(lower alkyl) or endo-(lower alkyl);is an integer of 2-4;R.sub.1 is --CH.sub.2 OH, --CHO, --CO.sub.2 R or --CO.sub.2 H, and the olefin formed by the R.sub.1 (CH.sub.2).sub.n CH.dbd. moiety is either (E) or (Z);R.sub.2 is hydrogen or methyl, or optionally --CH.dbd.CH.sub.2 when A is --CH.dbd.CHCH.sub.2 --; andR.sub.3 is linear or branched alkyl, alkenyl or alkynyl having 5-10 carbon atoms, ##STR2## --(CH.sub.2).sub.m -phenyl or CH.sub.
Abstract: Methods are provided for modulating Ligand-Receptor interactions by binding of molecules at two epitopes of a receptor, where the epitopes are in relatively close special relationship. By providing for inhibition of changes in conformation of the receptor, where the inhibition is due to steric interactions or molecular bridging between the two epitopic sites, Ligand-Receptor interactions may be modulated. The modulation of Ligand-Receptor interactions has application to diagnostic assays, modulation of cellular activity, and modulation of the physiological activity of macromolecular compounds.
Type:
Grant
Filed:
March 14, 1984
Date of Patent:
February 23, 1988
Assignee:
Syntex (U.S.A.) Inc.
Inventors:
Carl Skold, Dennis R. Gould, Edwin F. Ullman
Abstract: Heterocyclic aminoalkyl esters of mycophenolic acid, and the derivatives and pharmaceutically acceptable salts thereof, are useful as immunosuppressive agents, anti-inflammatory agents, anti-tumor agents, anti-viral agents, and anti-psoriatic agents.
Type:
Grant
Filed:
January 30, 1987
Date of Patent:
February 23, 1988
Assignee:
Syntex (U.S.A.) Inc.
Inventors:
Peter H. Nelson, Chee-Liang L. Gu, Anthony C. Allison, Elsie M. Eugui, William A. Lee
Abstract: A method of treating rheumatoid arthritis which method comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of the formula: ##STR1## and the pharmaceutically acceptable salts thereof, wherein:A is oxygen or sulfur;R.sup.1 is selected from the group consisting of H, ##STR2## in which Y is oxygen or sulfur:R.sup.2 is alkyl, haloalkyl or --NR.sup.4 R.sup.5, where R.sup.4 and R.sup.5 are independently H, alkyl, haloalkyl, cycloalkyl, phenyl optionally monosubstituted with halogen, hydroxy, carboxy, chlorocarbonyl, sulfonylamino, nitro, cyano, phenyl, alkyl, acyl, alkoxycarbonyl, acylamino, dialkylamino or dialkylaminoethoxycarbonyl, phenyl optionally disubstituted with hydroxy, carboxy, nitro or alkyl, or benzyl optionally substituted with dialkylamino;n is an integer from 0-6;R.sup.3 is H alkyl or a pharmaceutically acceptable cation;Q and R are independently H or --CO.sub.2 R.sup.
Type:
Grant
Filed:
January 23, 1986
Date of Patent:
February 16, 1988
Assignee:
Syntex (U.S.A.) Inc.
Inventors:
Peter H. Nelson, Anthony C. Allison, Elsie M. Eugui, Joseph M. Muchowski
Abstract: This invention concerns a new process of preparing optically active .alpha.-arylalkanoic acids and their precursors. These .alpha.-arylalkanoic acids, esters, amides, nitriles, oxazolines and metal salts are stereoselectively prepared by forming the metal or metal halide of the corresponding acid, ester, amide, oxazoline, nitrile, or metal salt and treating the compound so prepared with an aryl halide in the presence of a chiral (optically active) transition metal catalyst of the formula (LL*)QZT wherein Q is a transition metal selected from palladium and nickel; Z and T are independently halogen; and LL* is a chiral tertiary diphosphine compound capable of acting as a bidentate ligand with Q to form a 5-membered ring, optionally in the presence of a dipolar aprotic solvent or mixtures thereof, for a time sufficient to form the corresponding optically active .alpha.
Type:
Grant
Filed:
March 7, 1986
Date of Patent:
February 2, 1988
Assignee:
Syntex Pharmaceuticals International Ltd.
Abstract: Compounds having the formula ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the definitions given herein, are useful as antiarrhythmic agents.
Abstract: Methods are provided for rapidly determining a number of parameters in a few determinations. Particularly, the method is applicable to blood typing, determining the blood type as to the ABO and Rh type, as well as the determination of isoantibodies to the antigens. The method employs fluorescent particles having a plurality of fluorescers, where the presence or absence of light emission of a particular wavelength can be determined.
Abstract: 4-Monosubstitued and 4,6-disubstituted phenoxazines, methods of preparing them and pharmaceutical compositions containing them. These compounds are useful as anti-inflammatories.
Type:
Grant
Filed:
May 30, 1986
Date of Patent:
November 17, 1987
Assignee:
Syntex (U.S.A.) Inc.
Inventors:
Joseph M. Muchowski, Robert J. Greenhouse, Angel Guzman
Abstract: Compounds useful as antiviral agents are depicted in the formula: ##STR1## wherein: X is oxygen or NH, Y is hydrogen, iodo, fluoro, methyl or trifluoromethyl, Z is hydrogen or fluoro and Z' is fluoro; and the wavy line indicates that the group may be above or below the plane of the ring; and the pharmaceutically acceptable acid addition salts thereof.
Type:
Grant
Filed:
April 14, 1986
Date of Patent:
November 3, 1987
Assignee:
Syntex (U.S.A.) Inc.
Inventors:
Julien P. H. Verheyden, John C. Martin, G. V. Bindu Madhavan, Daniel P. C. McGee, Ernest J. Prisbe
Abstract: Compounds according to the formula ##STR1## , its optical isomers, or a pharmaceutically acceptable salt thereof wherein:m and n are integers of 1 to 6;R.sub.1 is hydrogen or alkyl of 1 to 4 carbons;R.sub.2 is hydrogen or R.sub.1 and R.sub.2 are combined to form an oxo group;R.sub.3 is hydrogen, alkyl of 1 to 6 carbons, phenyl, benzyl, hydroxy lower alkyl and its aliphatic acylates of 1 to 6 carbon atoms or aryl acylates of 7 to 12 carbon atoms, carbamoyl alkyl, carboxyalkyl, alkoxycarbonylalkyl or .alpha.-amino acid side chains;R.sub.4 is hydrogen, alkyl of 1 to 6 carbons, benzyl, or hydroxy lower alkyl;R.sub.5 is hydrogen, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms or cycloalkyl lower alkyl of 4 to 12 carbon atoms wherein the cycloalkyl ring is unsubstituted or substituted with a lower alkyl, lower alkoxy, --OH, --OCOR.sub.6, halo, --NH.sub.2, --N(R.sub.6).sub.2, --NHCOR.sub.6, --COOH, or --COO(R.sub.6) group wherein R.sub.
Abstract: Synthetic nonapeptide and decapeptide LHRH antagonist analogues having a halo lower alkyl guanadino-substituted amino acyl residue at position six are disclosed herein.
Abstract: Improved sensitive immunoassays are provided involving channeling involving one, usually two enzymes, where the enzymes are related by the product of one enzyme being the substrate of the other enzyme. A dispersed aggregation is formed in the assay medium of (1) the analyte, (2) one of the enzymes bound to a second binding member ("SBM") (enzyme - SBM conjugate) which conjugate is non-covalently bound to a first binding member ("FBM"), and (3) a multiplied amount of the other enzyme bound in the complex. The large amount of enzyme or reactant in the complex is achieved by having a multiplicity of linkages binding the enzyme or reactant directly or indirectly to FBMs. The enzyme channeling provides for a detectable signal which can be related to the amount of analyte in the medium.
Type:
Grant
Filed:
March 14, 1983
Date of Patent:
August 18, 1987
Assignee:
Syntex (U.S.A.) Inc.
Inventors:
Robert K. DiNello, Ian Gibbons, Edwin F. Ullman
Abstract: Compounds useful for treating inflammatory diseases, in particular rheumatoid arthritis, represented by the formula: ##STR1## and the pharmaceutically acceptable salts thereof, wherein:R.sub.1 is H or lower alkyl having 1 to 6 carbon atoms;R.sub.2 is H, lower alkyl having 1 to 6 carbon atoms or ##STR2## in which R.sub.3 is H, lower alkyl having 1 to 6 carbon atoms or a pharmaceutically acceptable cation;R.sub.4 and R.sub.5 are each independently H or lower alkyl having 1 to 6 carbon atoms;X and Y are each independently O or S; andn is an integer of 1-6.
Type:
Grant
Filed:
November 27, 1985
Date of Patent:
August 11, 1987
Assignee:
Syntex (U.S.A) Inc.
Inventors:
Peter H. Nelson, Anthony C. Allison, Elsie M. Eugui
Abstract: Solutions of choline base, (2-hydroxyethyl)trimethylammonium hydroxide, in water and/or lower alkanols may be stabilized by the addition of a stabilizing concentration of formaldehyde or paraformaldehyde. The stabilized solutions may be used as cleaning solutions, etchants for semiconductors and metal layers, and developers and strippers for positive working photoresists, and for other uses where a metal ion-free base is desired.